Neurocrine Biosciences, Inc. - Common Stock (NBIX)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 151% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 15.3% — good return on equity
- Revenue growing at 21% annually
Neurocrine Biosciences, Inc. - Common Stock (NBIX) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $15.9 billion . Key value metrics: P/E ratio 30.4, P/B ratio 4.67, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Neurocrine Biosciences, Inc. - Common Stock — Fundamental Analysis Summary
Neurocrine Biosciences, Inc. - Common Stock (NBIX) is currently trading 151% above its Graham Number of $62.96, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 30.4x.
On financial health, NBIX shows a moderate Piotroski F-Score of 4/9, and solid return on equity of 15.3% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.42.
StockPik's composite Value Score for NBIX is 52/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NBIX reports a high gross margin of 98.7% (sector average: 39.4%) and a strong operating margin of 21.0%.
NBIX shows revenue growing at 21% year-over-year, with earnings growing at 40%.